FDA Defends Drug Rejections & Cigna Acquires CarepathRx – Healthcare News Roundup

The week is winding down, and with it comes a fresh set of developments in the U.S. Healthcare landscape. This week brings scrutiny of decisions at the Food and Drug Administration, specifically regarding the approval of rare disease treatments, alongside a significant acquisition signaling further consolidation within the pharmaceutical supply chain. These events – one focused on access to innovative therapies, the other on controlling the flow of prescription drugs – highlight ongoing tensions between innovation, cost, and access in American healthcare.

FDA Commissioner Defends Agency’s Rejections of Rare Disease Therapies

FDA Commissioner Marty Makary is publicly defending the agency’s recent decisions to reject several cell and gene therapies targeting rare diseases. These rejections, and the role of Dr. Vinay Prasad, the FDA’s medical and scientific chief overseeing the biologics center, have sparked debate within the medical community and drawn criticism from some quarters. According to a STAT News report, at least five cell and gene therapies have been rejected or seen course corrections since modern leadership took the helm during the Trump administration.

Makary, in an interview with CNBC, described Prasad as a “genius” facing a “fatwa” and a “smear campaign” from certain media outlets. This strong defense comes in response to a Wall Street Journal editorial questioning Prasad’s role and alleging he’s demanding clinical trials that are prohibitively expensive and difficult to execute. The core of the dispute centers on the standards for evidence required to approve these potentially life-altering, but often very costly, treatments.

Cell and gene therapies represent a new frontier in medicine, offering the potential to cure diseases at their genetic root. However, these therapies are complex to develop and manufacture, and their long-term effects are often unknown. The FDA’s role is to balance the promise of these innovations with the require to ensure patient safety and efficacy. The agency’s decisions in these cases reflect a cautious approach, prioritizing rigorous clinical trials to establish clear benefits before granting approval. This approach, while intended to protect patients, can also delay access to potentially life-saving treatments.

Cigna’s Acquisition of CarepathRx: Expanding Control of the Pharmaceutical Supply Chain

In a separate but related development, Cigna has acquired CarepathRx, a large pharmacy services company backed by private equity. CarepathRx dispenses prescription drugs to approximately 10% of hospitals across the United States, as reported by STAT News. This acquisition is a significant step in Cigna’s strategy to exert greater control over the pharmaceutical supply chain and manage prescription drug costs.

Cigna’s 2018 acquisition of Express Scripts for $54 billion signaled the company’s intent to become a major player in pharmacy benefit management (PBM). PBMs act as intermediaries between drug manufacturers, insurance companies, and pharmacies, negotiating drug prices and managing prescription drug benefits for health plans. By acquiring CarepathRx, Cigna is extending its reach further into the healthcare system, directly controlling the dispensing of drugs to hospitals.

CarepathRx specializes in dispensing a range of drugs to hospitals, including specialty medications, infusion therapies, and drugs obtained through the 340B program. The 340B program allows eligible hospitals to purchase outpatient drugs at discounted prices, but it has been the subject of ongoing debate and scrutiny. Hospitals often utilize services like CarepathRx to manage their 340B program compliance and ensure patients have convenient access to their prescriptions while hospitalized.

Vertical Integration and its Implications

Cigna’s acquisition of CarepathRx is an example of vertical integration, where a company expands its control over multiple stages of the supply chain. This strategy can potentially lead to cost savings and improved efficiency, but it also raises concerns about reduced competition and increased market power. Critics argue that vertical integration can allow companies to stifle innovation and raise prices for consumers. The Federal Trade Commission (FTC) has been increasingly scrutinizing healthcare mergers and acquisitions to ensure they do not harm competition.

The trend towards vertical integration in the pharmaceutical industry is driven by several factors, including the rising cost of prescription drugs and the increasing complexity of the healthcare system. Companies are seeking ways to gain greater control over costs and improve their negotiating position with drug manufacturers. However, it remains to be seen whether these strategies will ultimately benefit consumers or simply lead to higher profits for large corporations.

What’s Next: Regulatory Scrutiny and Ongoing Debate

Both of these developments – the FDA’s approach to rare disease therapies and Cigna’s acquisition of CarepathRx – are likely to face continued scrutiny from regulators, policymakers, and patient advocacy groups. The FDA will likely be called upon to clarify its standards for approving cell and gene therapies, and to address concerns about potential delays in access to innovative treatments. The FTC will likely review Cigna’s acquisition of CarepathRx to assess its impact on competition and consumer prices.

The debate over drug pricing and access is likely to continue, with stakeholders on all sides advocating for their preferred solutions. Patient advocacy groups will continue to push for greater access to life-saving treatments, while insurance companies and PBMs will continue to emphasize the need to control costs. Finding a balance between innovation, affordability, and access will remain a major challenge for the U.S. Healthcare system.

Looking ahead, expect increased attention on the transparency of drug pricing and the role of PBMs in the pharmaceutical supply chain. There may also be renewed calls for legislative action to address the rising cost of prescription drugs and to ensure that patients have access to the treatments they need. The FDA will also likely continue to refine its regulatory framework for cell and gene therapies, balancing the need for innovation with the imperative to protect patient safety.